[Reinduction therapy with gemtuzumab ozogamicin for relapsed or refractory CD33-positive acute myelogeneous leukemia].

Abstract	The efficacy and safety of reinduction therapy with gemtuzumab ozogamicin (GO)were investigated in 7 patients with relapsed or refractory CD33-positive acute myelogeneous leukemia. As the administration method, intravenous drip infusion of 9 mg/m(2) was conducted on day 1 and 15. Though CR was attained in 3 patients, the remaining 4 patients were assessed as PD. Grade 3-4 neutropenia and thrombopenia occurred in all patients, 4 of whom were complicated with febrile neutropenia and 1 with new pneumonia. On the other hand, except for grade 1 digestive symptoms and grade 1 GPT increase, none of the patients had serious complications. Though the treatment with GO is considered comparatively safe, sufficient supportive therapy as in the case of conventional chemotherapy is necessary against hematological toxicity. The effect of monotherapy with GO in reinduction is limited. It is necessary to appropriately select the cases and to investigate an effective administration method including the concomitant use of antitumor agent.
Authors	Takayoshi Shimokawa, Yumi Kojima
Journal	Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 35 Issue 8 Pg. 1427-30 (Aug 2008) ISSN: 0385-0684 [Print] Japan
PMID	18701865 (Publication Type: Case Reports, Journal Article)
Chemical References	Aminoglycosides Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Antigens, CD Antigens, Differentiation, Myelomonocytic Antineoplastic Agents CD33 protein, human Sialic Acid Binding Ig-like Lectin 3 Gemtuzumab
Topics	Adult Aged Aminoglycosides (adverse effects, immunology, therapeutic use) Antibodies, Monoclonal (adverse effects, immunology, therapeutic use) Antibodies, Monoclonal, Humanized Antigens, CD (immunology) Antigens, Differentiation, Myelomonocytic (immunology) Antineoplastic Agents (adverse effects, therapeutic use) Female Gemtuzumab Humans Immunotherapy Leukemia, Myeloid, Acute (drug therapy, immunology) Male Middle Aged Recurrence Sialic Acid Binding Ig-like Lectin 3 Treatment Failure

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!